Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13743071 | 0.91 | — | — | |
| SCHEMBL8609056 | 0.89 | — | — | |
| SCHEMBL222372 | 0.88 | KCNA5 (0.61) | KCNA5ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL26247584 | 0.88 | — | — | |
| SCHEMBL26247580 | 0.88 | — | — | |
| SCHEMBL894866 | 0.88 | — | — | |
| SCHEMBL897672 | 0.88 | — | — | |
| SCHEMBL26247587 | 0.88 | — | — | |
| SCHEMBL30585369 | 0.88 | — | — | |
| SCHEMBL9188293 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | HK INNO.N CORPORATION (KR) | 2021-06-10 | — | — | US | claimed |
| EP-3478684-A1 | NEW PROCESSES FOR THE PREPARATION OF VEMURAFENIB | Fermion Oy (FI) | 2019-05-08 | — | — | EP | claimed |
| WO-2018002415-A1 | NEW PROCESSES FOR THE PREPARATION OF VEMURAFENIB | FERMION OY (FI) | 2018-01-04 | — | — | WO | claimed |
| WO-2012118492-A1 | HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| EP-2470538-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| CN-102459262-A | Pyrrolo [2, 3. b] pyridines which inhibit raf protein kinase | PLEXXIKON INC | 2012-05-16 | — | — | CN | disclosed |
| WO-2011025940-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| EP-2265608-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265574-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265610-A1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265609-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| WO-2009111277-A9 | IMIDAZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009143024-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111279-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111280-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111277-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | MAP3K20, MAP3K15, MAP3K1 | KCNA5 1719/4885ALDH1A1 4182/4885HPGD 2910/4885 |
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | KCNA5 4530/4885ALDH1A1 2072/4885HPGD 1061/4885 |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | KCNA5 1719/4885ALDH1A1 4182/4885HPGD 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.